<DOC>
	<DOCNO>NCT00003143</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Chemoprotective drug amifostine may protect normal cell side effect chemotherapy . PURPOSE : Randomized phase II trial study effectiveness combination chemotherapy without amifostine treat patient recurrent refractory non-Hodgkin 's lymphoma Hodgkin 's disease undergo autologous stem cell transplantation .</brief_summary>
	<brief_title>Combination Chemotherapy With Without Amifostine Treating Patients With Recurrent Refractory Non-Hodgkin 's Lymphoma Hodgkin 's Disease Undergoing Stem Cell Transplantation</brief_title>
	<detailed_description>OBJECTIVES : I . Evaluate role amifostine reduce hematologic toxicity improve mobilization peripheral progenitor stem cell patient recurrent refractory non-Hodgkin 's lymphoma Hodgkin 's disease undergo platinum base salvage chemotherapy . II . Evaluate role amifostine prevent renal toxicity patient . OUTLINE : This randomize , open label study . Patients randomize receive salvage chemotherapy intravenous dexamethasone/cisplatin/cytarabine ( DHAP ) without amifostine . Patients receive cisplatin IV 3 hour follow cytarabine IV 2 dos . Patients also receive dexamethasone orally IV . Treatment repeat every 3-4 week 2-6 course . Arm I : Patients receive amifostine IV 15 minute prior course DHAP , 15 minute infusion , begin 30 minute prior cisplatin administration . Arm II : Patients receive amifostine . On day 3 last DHAP course , patient receive filgrastim ( G-CSF ) last day progenitor stem cell ( PSC ) mobilization . PSC transplant continue daily 4-10 day . PROJECTED ACCRUAL : A total 40 patient ( 20 per treatment arm ) accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Amifostine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven recurrent refractory nonHodgkin 's lymphoma Hodgkin 's disease require salvage chemotherapy Prior treatment least 3 course first line chemotherapy PATIENT CHARACTERISTICS : Age : Over 18 Performance Status : ECOG 02 Life Expectancy : Greater 3 month Hematopoietic : Absolute neutrophil count least 1,500/mm3 Platelet count least 50,000/mm3 Hepatic : Not specify Renal : Creatinine great 1.5 mg/dL Creatinine clearance least 40 mL/min Cardiovascular : No symptomatic congestive heart failure ( class III define American Heart Association ) Electrolytes : Potassium least 3.4 meq/L Magnesium least 1.4 meq/L Other : Not pregnant nursing PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior high dose chemotherapy stem cell transplant At least 3 course first line chemotherapy Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>Waldenstr√∂m macroglobulinemia</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
</DOC>